503A vs 503B Compounding Pharmacy (2026)

Q: How do I verify the compounding pharmacy filling my GLP-1 prescription?

For a 503B facility, search the FDA registered outsourcing facilities list at fda.gov. For a 503A pharmacy, look up the license through your state board of pharmacy. Then search the FDA warning letter database and your state board disciplinary records for any red flags. Ask your provider to confirm API sourcing, sterility testing, and Beyond-Use Dating before you start.

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

If you’re researching compounded semaglutide or tirzepatide for weight loss, you’ve probably run into two pieces of regulatory shorthand: 503A and 503B. They aren’t marketing labels — they’re distinct sections of the Federal Food, Drug, and Cosmetic Act that determine who regulates a compounding pharmacy, what testing it must perform, how its medication can be distributed, and what you should ask before trusting it with your prescription. PlexusDx Weight Management Protocols — including Semaglutide Injection, Tirzepatide Injection, Microdose GLP-1 Protocol, and GLP-Squared — are filled by licensed U.S. compounding pharmacies. This article walks the actual regulatory framework so you can verify any compounder, including ours, and understand what the 503A/503B distinction does (and doesn’t) tell you about the medication arriving at your door.

503A vs 503B: the regulatory framework in one paragraph

Section 503A of the Federal Food, Drug, and Cosmetic Act — added by the FDA Modernization Act of 1997 — created the legal framework for traditional compounding pharmacies that prepare patient-specific medications based on a valid prescription. These pharmacies are regulated primarily by state boards of pharmacy and follow United States Pharmacopeia (USP) standards such as USP 795 and USP 797. Section 503B was added by the Drug Quality and Security Act of 2013 in response to the New England Compounding Center (NECC) tragedy and created a federal category called outsourcing facilities. 503B facilities register directly with the FDA, follow current Good Manufacturing Practices (cGMP) under 21 CFR Parts 210 and 211, and submit to routine FDA inspections. Neither 503A compounded medications nor 503B compounded medications are FDA-approved finished drug products — only branded products like Wegovy, Ozempic, Zepbound, and Mounjaro carry that designation. The 503A/503B distinction is about the regulatory pathway governing the pharmacy, not the molecule itself.

What a 503A compounding pharmacy actually does

Picture the traditional independent compounding pharmacy in your town. A licensed prescriber writes a patient-specific prescription — perhaps for a custom dose, an allergen-free formulation, or a strength that isn’t commercially available — and the pharmacist prepares that medication for that named patient. Under Section 503A, the pharmacy is exempt from federal cGMP and from full FDA new-drug-approval requirements, but it must use a valid prescription, follow USP chapters for compounding quality and sterility, and operate under state board of pharmacy oversight. The FDA does not routinely inspect 503A pharmacies; inspections happen on a risk-based basis when there is reason to suspect insanitary conditions or unsafe products. Distribution is restricted: a 503A pharmacy generally cannot ship more than 5% of its compounded prescriptions across state lines unless the home state has signed a Memorandum of Understanding (MOU) with the FDA. For patient-specific home-use medications — including most compounded GLP-1s shipped to telehealth patients today — this is the model in play.

What a 503B outsourcing facility actually does

503B outsourcing facilities exist because of the 2012 NECC fungal meningitis outbreak, in which contaminated steroid injections caused 64 deaths and more than 750 infections across 20 states. Congress responded by passing the Drug Quality and Security Act in 2013, which created the 503B category for compounders that wanted to manufacture in larger batches under federal oversight. A 503B facility registers with the FDA, follows cGMP under 21 CFR Parts 210 and 211, performs batch release testing, runs sterility testing on every lot of sterile drug product, validates its processes, qualifies its suppliers, maintains rigorous recordkeeping, and reports adverse events to the FDA. Routine FDA inspections happen on a risk-based schedule. Distribution is unrestricted: a 503B facility can supply hospitals, clinics, and 503A pharmacies nationwide, and does not need a patient-specific prescription for every batch. The FDA maintains a public list of registered 503B outsourcing facilities at fda.gov; if a pharmacy claims 503B status but isn’t on that list, it isn’t one.

The differences that actually matter for patients

Five practical differences separate 503A and 503B in ways that affect a patient’s medication. First, regulator: 503A is state-regulated, 503B is FDA-registered and FDA-inspected. Second, manufacturing standard: 503A follows USP 795/797, 503B must comply with cGMP. Third, batch testing: 503A is not federally required to perform batch release identity, potency, and sterility testing, while 503B must do so for every batch of sterile drug product. Fourth, prescription model: 503A requires a patient-specific prescription, 503B can supply healthcare facilities in bulk without one. Fifth, distribution: 503A interstate shipping is capped at 5% absent an MOU, while 503B can distribute nationally. Many telehealth GLP-1 programs use a hybrid — sometimes called the 503B-to-503A model under FDA draft guidance — in which a 503B facility manufactures the bulk drug under cGMP and a 503A pharmacy then dispenses patient-specific doses against named prescriptions. This combines federal manufacturing oversight with patient-specific dispensing, which is why the model is increasingly common in cash-pay weight-loss telehealth.

Is 503A or 503B safer? The honest answer

Designation is a regulatory label, not a safety guarantee. A well-run 503A pharmacy that follows USP 795 and USP 797 carefully, sources pharmaceutical-grade active pharmaceutical ingredients (APIs), and operates under rigorous state board oversight can produce safe medication. A 503B facility that lapses on cGMP can — and has — received FDA Form 483 observations or warning letters. What actually determines safety is the combination of: API sourcing (FDA-registered API supplier with a Drug Master File), sterility controls (USP 797 for sterile compounds, end-product sterility testing where applicable), Beyond-Use Dating supported by stability data rather than default literature limits, qualified personnel, documented quality systems, and a clean inspection history with the relevant regulator. PlexusDx’s position is straightforward: we use licensed U.S. compounding pharmacies that meet those substantive standards, and we don’t hide behind a designation as if it were proof of quality on its own. If you’re considering Semaglutide Injection, Tirzepatide Injection, or any other Weight Management Protocol, ask the same verification questions you would ask any compounder.

How to verify a compounding pharmacy: a five-step checklist

Use this checklist before trusting any compounder — PlexusDx’s pharmacy partners, a competitor’s pharmacy, or a local independent. Step 1: Confirm the designation. If the pharmacy claims 503B status, search the FDA’s registered outsourcing facilities list. If it claims 503A status, search your state board of pharmacy’s license lookup. Step 2: Verify licensing and registration. 503A pharmacies must be licensed by the state board of pharmacy where they operate and in any state they ship to that requires non-resident pharmacy licensure. 503B facilities must be FDA-registered. Both must register with the DEA if they handle controlled substances. Step 3: Check the public record. Search the FDA’s warning letter database, your state board’s disciplinary action records, and recall notices. Step 4: Ask the right questions. Where is the API sourced? Is it pharmaceutical-grade with a Drug Master File on file with the FDA? What sterility testing is performed? What is the Beyond-Use Date and what supports it? Is a Certificate of Analysis available on request? Step 5: Watch for warning signs. Marketing claims of “FDA-approved” on a compounded product, refusal to disclose the dispensing pharmacy, prices dramatically below market, or inability to verify state licensure are all reasons to walk away. Apply this checklist to any provider, including PlexusDx, before you start.

What 503A vs 503B means for compounded GLP-1 medications in 2026

Compounding of semaglutide and tirzepatide changed materially when the FDA removed both from the drug shortage list. Under current FDA guidance, 503A pharmacies may still compound semaglutide or tirzepatide when the prescriber documents a clinically significant difference between the compounded version and the commercially available branded product for the individual patient — for example, an alternative dose strength, a needle-free delivery format, or removal of an excipient the patient cannot tolerate. 503B outsourcing facilities face tighter restrictions because neither molecule appears on the 503B Bulks List and both have come off the shortage list. Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products under any pathway; only Wegovy, Ozempic, Rybelsus (semaglutide) and Zepbound, Mounjaro (tirzepatide) carry FDA approval. PlexusDx Weight Management Protocols dispense compounded GLP-1s through licensed U.S. compounding pharmacies operating within this framework, and our clinical team documents the patient-specific clinical justification when one is required.

Where PlexusDx fits — protocols, pricing, and the genetic baseline

PlexusDx offers six prescription compounds across four mechanism classes from $129/mo, available in all 50 states, with no membership fee. Microdose GLP-1 Protocol is $129/mo flat — compounded GLP-1 in capsule, troche, lozenge, or sublingual format. Semaglutide Oral runs from $209/mo across six dose levels (3mg to 24mg daily). Semaglutide Injection is $179–$229/mo across five weekly dose levels (0.25mg to 2.0mg). Tirzepatide Injection is $229–$309/mo across six dose levels (2.5mg to 15mg weekly). Tirzepatide Oral spans $229–$509/mo across seven dose levels (5mg to 25mg daily). GLP-Squared is the dual-compound semaglutide-plus-tirzepatide protocol at $179–$325/mo. All protocols are all-inclusive: async provider consultation, prescription, compounded medication, and shipping. Five states require a scheduled live consultation rather than async intake. Layer on the Precision Peptide Genetic Test — $298 standalone or $99 as an add-on after your first month — for 48 genes, 57 variants, 14 health pathways, and 150+ insights including the 34 weight-management insights anchored by the GIPR rs1800437 variant. The genetic baseline is a stratification step that compounding designation alone cannot provide.

Frequently asked questions

What is a 503A compounding pharmacy?

A 503A compounding pharmacy is a traditional pharmacy that prepares patient-specific medications under a valid prescription. It’s regulated primarily by the state board of pharmacy under Section 503A of the Federal Food, Drug, and Cosmetic Act, follows USP 795 and USP 797 standards, and is not required to register with the FDA or comply with cGMP.

What is a 503B outsourcing facility?

A 503B outsourcing facility is an FDA-registered compounder created by the Drug Quality and Security Act of 2013. It must comply with current Good Manufacturing Practices, perform batch release testing including sterility testing for every lot of sterile drug product, undergo routine FDA inspections, and report adverse events to the FDA. It can supply healthcare facilities in bulk without patient-specific prescriptions.

Are compounded GLP-1 medications FDA-approved?

No. Neither 503A nor 503B compounded medications are FDA-approved finished drug products. A 503B facility is FDA-registered and FDA-inspected, but the medications it compounds have not gone through the FDA new-drug approval process. Only branded products like Wegovy, Ozempic, Zepbound, and Mounjaro are FDA-approved.

Which compounding pharmacies does PlexusDx use?

PlexusDx Weight Management Protocols are filled by licensed U.S. compounding pharmacies. We do not name dispensing pharmacy partners publicly, but our pharmacies operate under appropriate state board licensure and applicable federal oversight, source pharmaceutical-grade active pharmaceutical ingredients, and follow USP standards for compounding quality and sterility.

Is a 503B pharmacy safer than a 503A pharmacy?

Designation alone does not equal safety. A well-run 503A pharmacy can produce safe medication and a 503B facility can receive FDA warning letters. Safety is determined by API sourcing, sterility controls, Beyond-Use Dating supported by stability data, qualified personnel, documented quality systems, and a clean inspection history — not by the regulatory label alone.

Can a 503A pharmacy ship compounded GLP-1s across state lines?

Limited. Under Section 503A, a pharmacy generally cannot ship more than 5% of its compounded prescriptions interstate unless its home state has signed a Memorandum of Understanding (MOU) with the FDA. Pharmacies that ship to all 50 states typically operate under MOU arrangements or partner with multiple licensed pharmacies to maintain compliance.

How do I verify the compounding pharmacy filling my GLP-1 prescription?

For a 503B facility, search the FDA’s registered outsourcing facilities list at fda.gov. For a 503A pharmacy, look up the license through your state board of pharmacy. Then search the FDA warning letter database and your state board’s disciplinary records for any red flags. Ask your provider to confirm API sourcing, sterility testing, and Beyond-Use Dating before you start.

503A vs 503B Compounding Pharmacy vs PlexusDx (2026): What Patients Actually Need to Know | PlexusDx

503A vs 503B compounding pharmacy explained — the regulatory framework, FDA Modernization Act of 1997 and Drug Quality and Security Act of 2013, oversight differences, and a five-step verification checklist for compounded GLP-1 medications.